Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07216482 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
A Phase 3 study of Hyperlipidemia, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 975
- Enrollment target
- 20
- Study locations
NCT07216482 is a Phase 3 study of Hyperlipidemia that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 975 participants, above the 380-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (157% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT07216482, a Phase 3 study of Hyperlipidemia, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 975 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to learn about giving enlicitide with another medicine called rosuvastatin. Rosuvastatin is a standard (usual) treatment to lower LDL-C. The goal of this study is to learn if enlicitide given with rosuvastatin works better than placebo on lowering LDL-C in a person's blood. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of a study medicine.
Conditions Studied
Interventions
- DRUG Rosuvastatin
- DRUG Enlicitide
- DRUG Placebo for Enlicitide
- DRUG Placebo for Rosuvastatin
Study Locations (20)
Florida
- Alliance for Multispecialty Research, LLC ( Site 0040) - Fort Myers
- Soffer Health Institute ( Site 0046) - Hollywood
- East Coast Institute for Research ( Site 0041) - Lake City
- Inpatient Research Clinic ( Site 0017) - Miami Lakes
- Clinical Research Trials of Florida ( Site 0001) - Tampa
- Clinical Site Partners LLC, dba CSP Orlando ( Site 0014) - Winter Park
Alabama
- Central Research Associates ( Site 0009) - Birmingham
- G&L Research ( Site 0024) - Foley
Arizona
- Synexus Clinical Research US, Inc. - Phoenix Central ( Site 0030) - Phoenix
- Alliance for Multispecialty Research LLC ( Site 0049) - Tempe
California
- Chemidox Clinical Trials ( Site 0008) - Lancaster
- Clinical Trials Research ( Site 0036) - Sacramento
Illinois
- Trialmed ( Site 0026) - Chicago
- Great Lakes Clinical Trials - Ravenswood ( Site 0018) - Chicago
Kansas
- Alliance for Multispecialty Research, LLC ( Site 0048) - Newton
- Cotton O'Neil Clinical Research Center ( Site 0006) - Topeka
Colorado
- Legacy Clinical Trials ( Site 0044) - Colorado Springs
Indiana
- Midwest Institute For Clinical Research ( Site 0033) - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 975 participants |
| Start Date | 2025-11-11 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07216482
The ClinicalTrials.gov registry entry for NCT07216482 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 975 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 380-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (157% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hyperlipidemia appearing as the primary indexed condition, and to 4 interventions - of which Rosuvastatin is the first listed.
NCT07216482 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT07216482 about?
NCT07216482 is a clinical study titled "A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)". Researchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to learn about giving enlicitide with another medicine called rosuvastatin. Rosuvastatin is a standard (usual) treatment to lower LDL-C. The goal of this stu...
What is the current status of trial NCT07216482?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 975 participants. The study started on 2025-11-11. Estimated completion is 2027-03-01.
What conditions does trial NCT07216482 study?
This clinical trial studies the following conditions: Hyperlipidemia.
What interventions are being tested in trial NCT07216482?
The interventions under investigation include: Rosuvastatin (DRUG), Enlicitide (DRUG), Placebo for Enlicitide (DRUG), Placebo for Rosuvastatin (DRUG).
Who is sponsoring clinical trial NCT07216482?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07216482 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperlipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
ACTIVE NOT RECRUITING · Phase 3
-
Low Carbohydrate Diet Compared to Calorie and Fat Restricted Diet in Patients With Obesity and Type II Diabetes
COMPLETED · Phase 3
-
Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy
COMPLETED · Phase 3
-
Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin
COMPLETED · Phase 3
-
Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
COMPLETED · Phase 3
-
A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.